---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018418"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:25:07.342248+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics Q1 net loss $9.3M ($0.31/share), revenue $0.5M, down 17% YoY

## Summary
- Revenue $0.5M ($0.3M product, $0.2M grant) vs $0.6M in Q1 2023.
- Operating loss $10.3M, net loss $9.3M, vs $10.0M and $5.8M prior year.
- Adjusted EBITDA loss $8.4M, up from $7.2M; cash & securities $50.0M.
- Appointed four new executives: President Richard Abbott, COO, CTO, CCO.
- Opened new manufacturing facility in Salt Lake; plans 510(k) submission for PCR Pro and COVID-19 test.

## SEC filing metadata
- accession: 0001493152-24-018418
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315224018418/0001493152-24-018418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315224018418/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018418
- JSON: https://secwatch.observer/filing/0001493152-24-018418.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018418.txt

## Key facts
- Earnings Releases
  Co-Diagnostics, Inc. reported quarter ended March 31, 2024 results: revenue $0.5 million, net income Net loss of $9.3 million, EPS loss of $0.31 per fully diluted share.
  - Period: quarter ended March 31, 2024
  - Revenue: $0.5 million
  - Net income: Net loss of $9.3 million
  - EPS: loss of $0.31 per fully diluted share
  - Result: reported results
  source text: Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results SALT LAKE CITY, May 9, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Dx,” or the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: ● Revenue of $0.5 million, down from $0.6 million during the prior year. Grant revenue totaled $0.2 million while product revenue totaled $0.3 million ● Operating expenses of $10.5 million increased by 4.4% from the prior year due to an increase in research and development costs incurred for the development of tests currently in our pipeline ● Operating loss of $10.3 million compared to operating loss of $10.0 million in Q1 2023 ● Net loss of $9.3 million, compared to net loss of $5.8 million in the prior year, representing a loss of $0.31 per fully diluted share, compared to a loss of $0.20 per fully dilut
  evidence_url: https://www.sec.gov/Archives/edgar/data/1692415/000149315224018418/0001493152-24-018418-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.